[Pubmed] Pembrolizumab-induced Myasthenia Gravis Relapse After Immunosuppressive Therapy

[RSS-Bot]

Intern Med. 2022 Apr 9. doi: 10.2169/internalmedicine.8554-21. Online ahead of print.

ABSTRACT

Myasthenia gravis (MG) is an immune-related adverse event (irAE), and as an irAE, MG (irAE-MG) generally has a monophasic course, with only a few case reports of irAE-MG flare-ups during the course of the disease. We herein report a case of pembrolizumab-induced MG with relapsing symptoms. irAE-MG is a rare disease that has not yet been fully characterized, and our case shows that MG symptoms may relapse. Therefore, regular follow-up is necessary, even after the symptoms improve with immunosuppressive therapy.

PMID:35400705 | DOI:10.2169/internalmedicine.8554-21


Source: https://pubmed.ncbi.nlm.nih.gov/3540070 ... 8&v=2.17.6